Exchange: NYSE·Updated 09:01 AM EDT
News
all
press releases
If You Invested $100 In Enova International Stock 10 Years Ago, You Would Have This Much Today
Enova International (NYSE:ENVA) has outperformed the market over the past 10 years by 25.66% on an annualized basis producing an average annual return of 39.04%. Currently, Enova International has a marketread more...
Benzinga
More News
Enova International, Inc. (ENVA) Hit a 52 Week High, Can the Run Continue?
Enova International (ENVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Enova International (ENVA) Is a Great Choice for 'Trend' Investors, Here's Why
Enova International (ENVA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks
3 Reasons Why Growth Investors Shouldn't Overlook Enova International (ENVA)
Enova International (ENVA) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zacks
Why Enova International (ENVA) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
4 Stocks With Solid Net Profit Margins to Boost Portfolio Returns
Here we present four stocks, HURN, EDRY, ENVA and QUAD, with solid net profit margins that can contribute to making a strong portfolio.
Zacks
Zacks.com featured highlights include OptimumBank, EuroDry, Enova International, Anika Therapeutics and The GEO
Recent price strength puts OptimumBank, EuroDry, Enova International, Anika Therapeutics and GEO in focus as August stocks with momentum.
Zacks
Pagaya's Q2 Earnings Beat and Higher Guidance Strengthen Growth Case
PGY's Q2 beat, record network volume and higher 2026 guidance strengthen its growth case, but execution remains key.
Zacks
PGY Looks Cheap, But Can Growth Outpace Execution and Funding Risks?
Pagaya trades below its industry P/B average, while rising earnings estimates and growth face funding-cost and execution risks.
Zacks
Pagaya Stock Rose 10.4% in a Week, But Can the Rally Continue Now?
PGY's 10.4% weekly gain follows stronger earnings, deeper funding and partner growth, but rising costs and concentration risks could test the rally.
Zacks

Advertisement|Remove ads.